Pivotal clinical trials for new drugs have historically lacked racial and ethnic diversity. Over the past decade, the National Institutes of Health, the Food and Drug Administration, and private industry have invested to address this problem. This has included guidance for sponsors, meetings, recommendations, and workshops. However, despite these attempts, most clinical trials do not recruit participants who accurately reflect the US population. This can lead to biased data and lack of trust in the approved medicine, and it reduces the value of the investment in clinical study.

AEI’s Kirsten Axelsen will host a panel of experts to discuss the root causes of the lack of clinical trial diversity, why it is important, and what policy changes could be made to achieve more accurate trial representation.

Photo credit: Shutterstock

Subscribe to AEI's YouTube Channel
https://www.youtube.com/user/AEIVideos?sub_confirmation=1

Like us on Facebook
https://www.facebook.com/AEIonline

Follow us on Twitter
https://twitter.com/AEI

For more information
http://www.aei.org

AEI operates independently of any political party and does not take institutional positions on any issues. AEI scholars, fellows, and their guests frequently take positions on policy and other issues. When they do, they speak for themselves and not for AEI or its trustees or other scholars or employees.

More information on AEI research integrity can be found here: http://www.aei.org/about/

#aei #news #politics #government #education #livestream #live #race #pharmaceutical #drugs #fda